Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis

James H. Tabibian, Felicity Enders, Mohamad H. Imam, Gururaj Kolar, Keith D. Lindor, Jayant A. Talwalkar

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction. Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be associated with CCA in a Japanese cohort of PSC patients. Our aim in this study was to determine whether IgE levels predict time to CCA, liver transplantation, or death in a Western (USA-based) cohort of PSC patients. Material and methods. Thirty-eight patients with PSC and IgE levels were identified and categorized into low or high IgE groups based on the sample median. Groups were compared with respect to clinical characteristics and adverse endpoint-free survival, and the association between IgE and endpoints was assessed with multivariate proportional-hazards models. Results. The median sample age at PSC diagnosis was 41 years, and median serum IgE level was 47.6 kU/L. Low and high IgE groups differed significantly only with respect to IgG subclasses, which were higher among the latter (p < 0.05). There were no significant differences in composite endpoint-free (p = 0.83) or CCA-free survival (p = 0.20). In multivariate analyses, only Mayo PSC risk score and MELD score were significant predictors of endpoint-free survival (p < 0.05). Conclusions. Serum IgE level is associated with several IgG subclass levels but not time to CCA, liver transplantation, or death among PSC patients in a USA-based cohort. While Mayo PSC risk score and MELD score can predict these outcomes, more specific predictors of CCA are needed.

Original languageEnglish (US)
Pages (from-to)384-389
Number of pages6
JournalAnnals of Hepatology
Volume13
Issue number3
StatePublished - 2014
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Immunoglobulin E
Cholangiocarcinoma
Serum
Survival
Liver Transplantation
Immunoglobulin G
Free Association
Proportional Hazards Models
Multivariate Analysis

Keywords

  • Antibodies
  • Autoimmune diseases
  • Cholangiocarcinoma
  • Liver transplantation
  • Outcomes

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Tabibian, J. H., Enders, F., Imam, M. H., Kolar, G., Lindor, K. D., & Talwalkar, J. A. (2014). Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Annals of Hepatology, 13(3), 384-389.

Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. / Tabibian, James H.; Enders, Felicity; Imam, Mohamad H.; Kolar, Gururaj; Lindor, Keith D.; Talwalkar, Jayant A.

In: Annals of Hepatology, Vol. 13, No. 3, 2014, p. 384-389.

Research output: Contribution to journalArticle

Tabibian, JH, Enders, F, Imam, MH, Kolar, G, Lindor, KD & Talwalkar, JA 2014, 'Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis', Annals of Hepatology, vol. 13, no. 3, pp. 384-389.
Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Annals of Hepatology. 2014;13(3):384-389.
Tabibian, James H. ; Enders, Felicity ; Imam, Mohamad H. ; Kolar, Gururaj ; Lindor, Keith D. ; Talwalkar, Jayant A. / Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. In: Annals of Hepatology. 2014 ; Vol. 13, No. 3. pp. 384-389.
@article{22b849f923304604b008f42a1a787a0e,
title = "Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis",
abstract = "Introduction. Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be associated with CCA in a Japanese cohort of PSC patients. Our aim in this study was to determine whether IgE levels predict time to CCA, liver transplantation, or death in a Western (USA-based) cohort of PSC patients. Material and methods. Thirty-eight patients with PSC and IgE levels were identified and categorized into low or high IgE groups based on the sample median. Groups were compared with respect to clinical characteristics and adverse endpoint-free survival, and the association between IgE and endpoints was assessed with multivariate proportional-hazards models. Results. The median sample age at PSC diagnosis was 41 years, and median serum IgE level was 47.6 kU/L. Low and high IgE groups differed significantly only with respect to IgG subclasses, which were higher among the latter (p < 0.05). There were no significant differences in composite endpoint-free (p = 0.83) or CCA-free survival (p = 0.20). In multivariate analyses, only Mayo PSC risk score and MELD score were significant predictors of endpoint-free survival (p < 0.05). Conclusions. Serum IgE level is associated with several IgG subclass levels but not time to CCA, liver transplantation, or death among PSC patients in a USA-based cohort. While Mayo PSC risk score and MELD score can predict these outcomes, more specific predictors of CCA are needed.",
keywords = "Antibodies, Autoimmune diseases, Cholangiocarcinoma, Liver transplantation, Outcomes",
author = "Tabibian, {James H.} and Felicity Enders and Imam, {Mohamad H.} and Gururaj Kolar and Lindor, {Keith D.} and Talwalkar, {Jayant A.}",
year = "2014",
language = "English (US)",
volume = "13",
pages = "384--389",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "3",

}

TY - JOUR

T1 - Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis

AU - Tabibian, James H.

AU - Enders, Felicity

AU - Imam, Mohamad H.

AU - Kolar, Gururaj

AU - Lindor, Keith D.

AU - Talwalkar, Jayant A.

PY - 2014

Y1 - 2014

N2 - Introduction. Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be associated with CCA in a Japanese cohort of PSC patients. Our aim in this study was to determine whether IgE levels predict time to CCA, liver transplantation, or death in a Western (USA-based) cohort of PSC patients. Material and methods. Thirty-eight patients with PSC and IgE levels were identified and categorized into low or high IgE groups based on the sample median. Groups were compared with respect to clinical characteristics and adverse endpoint-free survival, and the association between IgE and endpoints was assessed with multivariate proportional-hazards models. Results. The median sample age at PSC diagnosis was 41 years, and median serum IgE level was 47.6 kU/L. Low and high IgE groups differed significantly only with respect to IgG subclasses, which were higher among the latter (p < 0.05). There were no significant differences in composite endpoint-free (p = 0.83) or CCA-free survival (p = 0.20). In multivariate analyses, only Mayo PSC risk score and MELD score were significant predictors of endpoint-free survival (p < 0.05). Conclusions. Serum IgE level is associated with several IgG subclass levels but not time to CCA, liver transplantation, or death among PSC patients in a USA-based cohort. While Mayo PSC risk score and MELD score can predict these outcomes, more specific predictors of CCA are needed.

AB - Introduction. Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be associated with CCA in a Japanese cohort of PSC patients. Our aim in this study was to determine whether IgE levels predict time to CCA, liver transplantation, or death in a Western (USA-based) cohort of PSC patients. Material and methods. Thirty-eight patients with PSC and IgE levels were identified and categorized into low or high IgE groups based on the sample median. Groups were compared with respect to clinical characteristics and adverse endpoint-free survival, and the association between IgE and endpoints was assessed with multivariate proportional-hazards models. Results. The median sample age at PSC diagnosis was 41 years, and median serum IgE level was 47.6 kU/L. Low and high IgE groups differed significantly only with respect to IgG subclasses, which were higher among the latter (p < 0.05). There were no significant differences in composite endpoint-free (p = 0.83) or CCA-free survival (p = 0.20). In multivariate analyses, only Mayo PSC risk score and MELD score were significant predictors of endpoint-free survival (p < 0.05). Conclusions. Serum IgE level is associated with several IgG subclass levels but not time to CCA, liver transplantation, or death among PSC patients in a USA-based cohort. While Mayo PSC risk score and MELD score can predict these outcomes, more specific predictors of CCA are needed.

KW - Antibodies

KW - Autoimmune diseases

KW - Cholangiocarcinoma

KW - Liver transplantation

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84901412280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901412280&partnerID=8YFLogxK

M3 - Article

C2 - 24756015

AN - SCOPUS:84901412280

VL - 13

SP - 384

EP - 389

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 3

ER -